Stem Cell Differentiation

Stem Cell Differentiation describes the progressive developmental process transforming pluripotent or multipotent stem cells into specialised cell types with distinct morphologies, functions, and gene expression patterns through orchestrated changes in transcriptional programmes, epigenetic modifications, and cellular signalling. This fundamental biological process drives embryonic development, maintains adult tissues, and enables regenerative medicine applications, guided by growth factors, cytokines, small molecules, and mechanical cues.

The biopharmaceutical industry leverages stem cell differentiation across therapeutic development, disease modelling, and drug screening applications. Cell therapy products employ controlled differentiation protocols generating specific cell types from pluripotent or multipotent precursors for transplantation, with regulatory approval obtained for retinal pigment epithelium treating macular degeneration and clinical trials ongoing for cardiac, neural, and pancreatic cell replacement. Disease modelling differentiates patient-derived iPSCs carrying disease mutations into affected cell types, enabling mechanistic studies and drug screening. Pharmaceutical safety testing employs differentiated cardiomyocytes, hepatocytes, or neurones providing human-relevant toxicity assessment. Manufacturing challenges include achieving reproducible differentiation at scale, removing undifferentiated cells posing teratoma risks, and demonstrating consistent product quality. As protocols improve and manufacturing processes mature, stem cell differentiation applications expand enabling cell therapies, disease modelling, and safety testing supporting therapeutic innovation.